started · updated
India cracks down on high‑risk drug manufacturers and medical stores
India’s drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has taken enforcement action against about 90% of the more than 960 high‑risk pharmaceutical facilities inspected since late 2022, affecting roughly 860 sites. Measures include stop‑production orders, licence suspensions and cancellations, and are part of a risk‑based inspection framework that aligns manufacturers with World Health Organization standards, with a compliance deadline of Dec 31. The crackdown follows global scrutiny after Indian‑made cough syrups were linked to child deaths in several countries, and the agency is using digital tools and artificial‑intelligence systems to support inspections and adverse‑event reporting.
Separately, the Rajasthan state government has permanently revoked the drug licences of 31 medical stores after an AI‑based audit uncovered fraudulent claims under the Rajasthan Government Health Scheme. The audit found fake doctor signatures, inflated prices and claims for non‑covered items, especially for drugs such as Exemptia 40 mg, Denberi injection, Terifrac and Trulicity 1.5 mg. The action includes recovery of excess payments, temporary suspension of TMS services for ten stores, and broader efforts to improve transparency and accountability in the Indian pharmaceutical sector.
Entities
Central Drugs Standard Control Organisation · Rajasthan Government Health Scheme · Rajasthan State Health Assurance Agency · Rajeev Raghuvanshi · World Health Organization
Claims
What the coverage asserts, and how many sources carry each claim.
- [○ 1 SOURCE] An AI‑based monitoring system identified fake doctor signatures, inflated prices and non‑covered items in claims. thecsrjournal.in
- [○ 1 SOURCE] Temporary suspension of TMS services was ordered for ten medical stores and excess payments are being recovered. thecsrjournal.in
- [○ 1 SOURCE] Excessive pricing was found for Exemptia 40 mg, Denberi injection, Terifrac and Trulicity 1.5 mg. thecsrjournal.in
- [● 2 SOURCES] Inspections were conducted under a risk‑based framework that assesses manufacturing sites and testing labs. kfgo.com · wtvbam.com
- [● 2 SOURCES] Manufacturers were required to align with World Health Organization standards, with a compliance deadline of Dec 31. kfgo.com · wtvbam.com
- [● 2 SOURCES] India’s drug regulator took enforcement action against about 90% of inspected high‑risk pharmaceutical facilities, roughly 860 of more than 960 inspections. kfgo.com · wtvbam.com
- [○ 1 SOURCE] Rajasthan revoked licences of 31 medical stores for fraudulent claims under the Rajasthan Government Health Scheme. thecsrjournal.in
- [● 2 SOURCES] The enforcement actions included stop‑production orders, licence suspensions and cancellations. kfgo.com · wtvbam.com